Drug name - Corlanor

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Jun, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 7.5MG BASE TABLET;ORAL Prescription
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

Drugs and Companies using IVABRADINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/5ML (1MG/ML) SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.